Internal Medicine, Hematology & Oncology · Omaha, NE
NPI
1205816667
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8303 Dodge St, Suite 250
Omaha, NE, 68114
Phone (402) 354-8124
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.0M
360,918 services
Medicare patients, 2024
973
Average age 76
Drug cost, 2024
$11.9M
3,792 prescriptions
Company payments, 2025
$548
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stefano Tarantolo was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 54,900 times for 35 patients. In total Stefano Tarantolo billed 360,918 services in 190 codes, and Medicare paid $7.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 54,900 | 35 | $38.98 | $2.1M |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 48,750 | 39 | $0.86 | $42K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 24,180 | 44 | $35.80 | $866K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 13,940 | 14 | $2.33 | $33K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 10,050 | 24 | $0.11 | $1,120 |
| J0897 Injection, denosumab, 1 mg | Office | 8,340 | 23 | $20.66 | $172K |
| J9071 Injection, cyclophosphamide (auromedics), 5 mg | Office | 7,931 | 11 | $1.16 | $9,187 |
| J9041 Injection, bortezomib, 0.1 mg | Office | 7,770 | 18 | $1.38 | $11K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 6,204 | 24 | $20.12 | $125K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 6,130 | 25 | $31.48 | $193K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 4,200 | 15 | $44.60 | $187K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,289 | 84 | $0.09 | $289 |
| 85025 Blood Count | Office | 2,486 | 460 | $7.57 | $19K |
| 80053 Clinical Chemistry | Office | 1,782 | 420 | $10.28 | $18K |
| 99214 Office E&M - Established | Office | 1,710 | 610 | $86.90 | $149K |
By year: 2022 $6.0M for 278,301 services; 2023 $5.6M for 287,311 services; 2024 $7.0M for 360,918 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,486 | 460 | $7.57 | $19K |
| 80053 Clinical Chemistry | 1,782 | 420 | $10.28 | $18K |
| 83615 Clinical Chemistry | 875 | 328 | $5.89 | $5,154 |
| 88185 Surgical Pathology Examination | 608 | 29 | $16.60 | $10K |
| 82728 Clinical Chemistry | 181 | 90 | $13.31 | $2,409 |
| 36415 Venipuncture Blood Collection | 138 | 97 | $8.27 | $1,142 |
| 85651 Clinical Chemistry | 127 | 100 | $4.16 | $528 |
| 84443 Clinical Chemistry | 95 | 49 | $16.29 | $1,547 |
| 80048 Clinical Chemistry | 43 | 26 | $8.29 | $356 |
| 82565 Clinical Chemistry | 43 | 36 | $5.02 | $216 |
Medicare prescription drug claims, 2024
In 2024, the drug Stefano Tarantolo prescribed most often to Medicare patients was Acyclovir, with 658 prescriptions and refills. In total Stefano Tarantolo wrote 3,792 Medicare prescriptions that cost $11.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 658 | 1,259 | 148 | $11K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 427 | 862 | 106 | $2,815 |
| Potassium Chloride Generic | 146 | 237 | 37 | $2,288 |
| Brukinsa Zanubrutinib | 141 | 141 | 18 | $1.5M |
| Pantoprazole Sodium Generic | 127 | 222 | 25 | $947 |
| Gabapentin Generic | 126 | 185 | 28 | $1,677 |
| Revlimid Lenalidomide | 124 | 124 | 27 | $2.6M |
| Dexamethasone Generic | 121 | 168 | 54 | $4,475 |
| Pomalyst Pomalidomide | 114 | 114 | 13 | $2.6M |
| Eliquis Apixaban | 99 | 129 | 14 | $74K |
| Ondansetron Hcl Generic | 95 | 95 | 66 | $817 |
| Montelukast Sodium Generic | 90 | 121 | 42 | $434 |
| Dapsone Generic | 90 | 197 | 24 | $8,117 |
| Lenalidomide Generic | 84 | 84 | 18 | $1.2M |
| Prochlorperazine Maleate Generic | 80 | 80 | 59 | $792 |
Brand drugs: - claims; generic drugs: 2,928 claims; opioid claims: 81.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stefano Tarantolo $548 ($548 in general payments such as food, travel and fees) from 15 companies. The largest payer was BeOne Medicines USA, Inc. with $149.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.